Efficacy and safety of XEN®-Implantation vs. trabeculectomy: Data of a "real-world" setting

被引:59
|
作者
Wagner, Felix Mathias [1 ]
Schuster, Alexander Karl-Georg [1 ]
Emmerich, Julia [1 ]
Chronopoulos, Panagiotis [1 ]
Hoffmann, Esther Maria [1 ]
机构
[1] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Ophthalmol, Mainz, Germany
来源
PLOS ONE | 2020年 / 15卷 / 04期
关键词
MINIMALLY INVASIVE GLAUCOMA; OPEN-ANGLE GLAUCOMA; TREATMENT OUTCOMES; RISK-FACTORS; SURGERY; IMPLANT; FAILURE; TUBE;
D O I
10.1371/journal.pone.0231614
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective To compare surgical success, postoperative intraocular pressure and complication rates between trabeculectomy and XEN gelstent surgery in a cohort of glaucoma patients in a typical clinical setting. Methods A retrospective cohort study of consecutive patients with refractory open-angle glaucoma including patients who underwent either stand-alone XEN gelstent insertion with Mitomycin C or trabeculectomy with Mitomycin C between 2016 and 2018 at the University Eye Hospital Mainz, Germany. Primary outcome measure was the proportion of surgical success 1 year after surgery. Patients with an IOP <= 18mmHg, an intraocular pressure reduction of >20% and in no need of revision surgery or topical medication were considered a complete surgical success. If topical therapy was necessary, they were considered a qualified success. Multivariable logistic regression analysis was carried out for the primary outcome including gender, age, preoperative intraocular pressure and number of medication classes used preoperatively as adjustment variables. Results 171 eyes of 144 patients were included, including 82 eyes of 58 patients in the XEN group and 89 eyes of 86 patients in the trabeculectomy group. The primary outcome defined as the proportion of surgical success after 1 year (mean 11.1 months +/- 2.2) was similar for both groups. The complete success proportion was 65.5% (95%-CI: 55.6-75.9%) in the trabeculectomy group, and 58.5% (95%-CI: 47.6-69.4%) in the XEN group and not statistically different in our analysis model (crude OR = 0.61; 95%-CI: 0.31-1.22; adjusted OR = 0.66; 95%-CI: 0.32-1.37). The intraocular pressure reduction, as secondary outcome measure, was higher in the trabeculectomy group (10.5 mmHg) compared to the XEN group (7.2 mmHg; p = 0.003) at the 12-month follow-up. Conclusion Both XEN gelstent implantation and trabeculectomy show similar proportions of surgical success and of complications and are therefore both recommendable for clinical routine. However, trabeculectomy seems to be more effective in lowering intraocular pressure than the XEN implantation. A prospective randomized clinical trial is necessary to evaluate differences in the long-term clinical outcome.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Belatacept vs. Tacrolimus in the Real World: An Efficacy and Safety Analysis
    Arazo, Karen Sofia K. Gonzalez
    Sleiman, Jihan J.
    Laham, Gustavo G.
    Pujol, Gervasio G. Soler
    Diaz, Carlos C.
    [J]. TRANSPLANTATION, 2022, 106 (09) : S155 - S155
  • [2] Efficacy of Omalizumab in a real-world setting
    Sussman, Robert
    [J]. CHEST, 2007, 132 (04) : 512S - 512S
  • [3] The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting
    Obi, Shuntaro
    Sato, Takahisa
    Sato, Shinpei
    Kanda, Miho
    Tokudome, Yuta
    Kojima, Yuichiro
    Suzuki, Yoji
    Hosoda, Kenji
    Kawai, Toshihiro
    Kondo, Yuji
    Isomura, Yoshihiro
    Ohyama, Hiroshi
    Nakagomi, Keiko
    Ashizawa, Hiroshi
    Miura, Yuko
    Amano, Hiroyuki
    Mochizuki, Hitoshi
    Omata, Masao
    [J]. HEPATOLOGY INTERNATIONAL, 2019, 13 (02) : 199 - 204
  • [4] Clinical efficacy and safety of secukinumab for psoriasis in a real-world setting in Turkey
    Yildirim, Fatma Elif
    Hapa, Fatma Asli
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1531 - 1537
  • [5] The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting
    Shuntaro Obi
    Takahisa Sato
    Shinpei Sato
    Miho Kanda
    Yuta Tokudome
    Yuichiro Kojima
    Yoji Suzuki
    Kenji Hosoda
    Toshihiro Kawai
    Yuji Kondo
    Yoshihiro Isomura
    Hiroshi Ohyama
    Keiko Nakagomi
    Hiroshi Ashizawa
    Yuko Miura
    Hiroyuki Amano
    Hitoshi Mochizuki
    Masao Omata
    [J]. Hepatology International, 2019, 13 : 199 - 204
  • [6] Efficacy and safety of filgrastim biosimilar Accofil® - real-world data
    Denzlinger, C.
    Taenzer, M.
    Kahner-Groene, S.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 239 - 239
  • [7] Conundrum of Using Real-World Observational Data to Inform Real-World Conclusions About Safety and Efficacy
    Gibson, C. Michael
    Nafee, Tarek
    Kerneis, Mathieu
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (15) : 1801 - 1803
  • [8] Real-world efficacy and safety of brolucizumab
    Walter, Scott
    Saba, Nicholas
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [9] Efficacy, tolerability and safety of teriflunomide in multiple sclerosis in a real-world clinical setting
    Oreja-Guevara, C.
    Orviz-Garcia, A.
    Guerra-Schulz, E.
    Lopez de Velasco, V.
    Lopez-Perez, F.
    Palacios, M.
    Gonzalez-Suarez, I.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 544 - 544
  • [10] Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison
    Cheng, Linyan
    Chen, Lujun
    Shi, Yuan
    Gu, Weiying
    Ding, Weidong
    Zheng, Xiao
    Liu, Yan
    Jiang, Jingting
    Zheng, Zhuojun
    [J]. MOLECULAR CANCER, 2024, 23 (01)